Clinical Trial

Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy

Study acronym: NIVO-LD
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate whether a single dose of Nivolumab in people living with HIV can reduce the latent reservoir. The latent HIV reservoir is a group of immune system cells in the body that are infected with HIV but are not actively producing new virus. This is the reason why people living with HIV are unable to stop their antiretroviral treatment.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-01-09; most recent amendment 2025-12-15.
Status change: Not Yet Recruiting → Recruiting 2023-02-05
Trial Details
NCT Number NCT05187429
Lead Sponsor University of Melbourne
Collaborators: The Alfred, NCID
Conditions HIV I Infection
Enrollment 42 participants
Start Date 2023-01-24
Primary Completion 2029-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-22